---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011069"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:46:42.133698+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M

## Summary
- Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.
- Cash and equivalents $1.8M at March 31, 2025, down from $5.9M at Dec 31, 2024.
- Phase 3 trial for Ameluz in actinic keratoses on extremities, neck and trunk enrolled final patient; Phase 3 sBCC study completed 1-year follow-up.
- Phase 2b study for Ameluz in moderate to severe acne vulgaris completed patient enrollment.
- Patent approval extended Ameluz protection to December 2043 for revised formulation.

## SEC filing metadata
- accession: 0001641172-25-011069
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/0001641172-25-011069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000164117225011069/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011069
- JSON: https://secwatch.observer/filing/0001641172-25-011069.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.